List of Filspari drug patents
Filspari is owned by Travere.
Filspari contains Sparsentan.
Filspari has a total of 1 drug patent out of which 0 drug patents have expired.
Filspari was authorised for market use on 17 February, 2023.
Filspari is available in tablet;oral dosage forms.
Filspari can be used as treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression.
Drug patent challenges can be filed against Filspari from 2027-02-17.
The generics of Filspari are possible to be released after 29 March, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993461 | TRAVERE | Method for treating disorders associated with glomerular function |
Mar, 2030
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 17, 2030 |
| New Chemical Entity Exclusivity (NCE) | Feb 17, 2028 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 2027-02-17
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic